Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661608 | 1.00 | AOC3 (0.37) | AOC3AXLMEN1ALDH1A1POLB | |
| SCHEMBL17041206 | 0.86 | MAPT (0.35) | AXLMEN1ALDH1A1POLBMAPT | |
| SCHEMBL29661294 | 0.86 | MAPT (0.35) | AXLMEN1ALDH1A1POLBMAPT | |
| SCHEMBL4492757 | 0.73 | CYP3A4 (0.34) | ALDH1A1POLB | |
| SCHEMBL20392875 | 0.73 | AOC3 (0.37) | AOC3ALDH1A1 | |
| SCHEMBL21552685 | 0.73 | AOC3 (0.37) | AOC3 | |
| SCHEMBL15688428 | 0.73 | AOC3 (0.37) | AOC3 | |
| SCHEMBL19122860 | 0.73 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL31042474 | 0.71 | AOC3 (0.40) | AOC3 | |
| SCHEMBL25310588 | 0.70 | AOC3 (0.39) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005638-A | Pyrazolo [3,4-d ] pyrimidine structure-containing compound, and preparation method and application thereof | 西安新通药物研究股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117580849-A | Steroid compound, pharmaceutical composition and application thereof | 江苏先声药业有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-111825701-B | Tricyclic FXR modulator compounds containing benzothiazole | 正大天晴药业集团股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4169904-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022268176-A1 | STEROID COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 江苏先声药业有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022206531-A1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 西安新通药物研究股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
| CN-111825701-A | Tricyclic FXR modulator compounds containing benzothiazole | 正大天晴药业集团股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | AOC3 4715/4885AXL 81/4885MEN1 1963/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | AOC3 3648/4885AXL 25/4885MEN1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.